



















Principal Sponsor

Bellberry Limited supporting research and ethics

NATIONAL · INDEPENDENT · NOT-FOR-PROFIT · SPECIALIST HREC PROVIDER

Our core objectives — to protect the welfare of human research participants, and to improve quality, efficiency and effectiveness of research.







JOIN US...HERE



for a front-row seat to some of the most exciting science in the country and around the world.

bellberry.com.au



Download the APSA-ASCEPT 2022 Joint Conference app

The Event App by EventsAIR includes everything you need to know about the conference, including the program, symposia, speakers, abstracts, social program, sponsors and exhibitors and the venue. Use the app to build your own conference agenda and contact other delegates via the app.

To download the app to your phone or tablet, scan the appropriate QR code below:









To download to your computer, laptop or other device, follow the link from the conference website: www.apsa-ascept2022.com/app

The first time you open the app, you will need to enter this code: apsa-ascept

Then, log in using your account email address and PIN supplied in your final confirmation email.

When you download the app, please opt in so that you are able to use all of the interactive features and send messages to other delegates.

If you have any problems downloading and accessing the app, please see the staff at the registration desk.



Engage with us on Twitter for your chance to win a cash prize

Most engaging tweet - #APSA ASCEPT2022 - \$200 prize Sponsor quiz - #APSA ASCEPTSponsors - \$200 prize Best conference photo - #APSA ASCEPTPhotos - \$100 prize Further information is available at the registration desk or via the conference app.

Social Media Policy

Conference attendees must gain approval from a speaker or poster presenter prior to quoting or publishing that individual's specific scientific result on any forum cial Media including social media. We respectfully ask that if you attend a presentation where a presenter has communicated that they do not wish to have their presentation commented on in the social media environment

that you adhere to this request.

Presenters, if you are presenting preliminary or unpublished data, and do not wish the results to be broadcast, please use the following logo with your presentation asking the audience to refrain from posting your material. It should appear on the title slide or poster, and if you like, any slides you do not want posted or commented on, so that your audience recognises your request

"I request that my presentation is not recorded, photographed, commented on or posted about on social media or in any other forum.

Thank you.

Tuesday 29 November 2022		Pre-conference workshops
08:30 – 18:00 Registration desk open Crown Ballroom Foyer		
09:00 – 12:00	09:30 – 12:00	09:30 – 12:30
Pharmacogenomics SIG workshop - PGx, is it time to be precise?	Toxicology SIG workshop - Health misinformation in the age of the pandemic	APSA-ASCEPT Joint Education workshop - Research skills acquisition
Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 3C
Facilitator: Zeyad Ibrahim Opening Address, Prof Andrew Somogyi	Chairs: Tayler Kent, Murdoch University and Dr Susan Britza, The University of Adelaide How did we get here? A history of	Chairs: Dr Sarira El-Den, Assoc Prof Tina Hinton, Assoc Prof Lynette Fernandes Facilitator: Dr Anna-Marie Babey
Interaction of PGxs with Pharmacometric and modelling platform, Prof Joseph Ciccolini, University of Marseille, France	pandemics and misinformation, Tayler Kent, Murdoch University Herbal misinformation and	Essential research skills, Assoc Prof David Foster, University of South Australia and Prof Jan-Willem Alffenaar, The University of Sydney
Pharmacogenomic implications of polypharmacy in hospitalised patients taking antipsychotic medications Dr Vijay Suppiah, University of South Australia	misrepresentation: Safety concerns in times of crisis, Dr Susan Britza, The University of Adelaide Using social media as a tool for health literacy in the pandemic, Dr Jessica	Presentations by: Tori Llewelyn, Flinders University Slade Matthews, The University of Sydney Rebekah Moles, The University of Sydney Alison Shield, The University of Canberra
Gene S Presentation, Dr Svetlana Baltic	Stokes-Parish, Bond University	Souha Youssef, University of South Australia
PGx Perceptions in WA Pharmacy Schools, Assoc Prof Phil Burcham, University of Western Australia	So what do we do about misinformation? Dr Ian Musgrave, The University of Adelaide	Comfort break Group discussion Comfort break
Morning tea	Investigating the regulatory compliance of herbal weight loss supplements in Australia, Emily Davies, Murdoch University	12:00 – 12:30 ASCEPT Education Forum AGM / APSA networking chat
Australian Genomics Project: Indications for pharmacogenomics testing in Australia, Dr Stephen Hughes, Royal College of Pathology Australasia	Dr David Robert Grimes, University of Dublin, Ireland	
11:45 – 12:00 Pharmacogenomics SIG AGM Chair: Prof Andrew Somogyi	11:45 – 12:00 Toxicology SIG AGM	

Tuesday 29 November 2022 continu	ed	Pre-conference workshops
12:15 – 14:15	12:15 – 14:15	13:30 – 16:30
APSA-ASCEPT Joint Careers workshop	Drug Disposition and Response SIG workshop	Clinical Pharmacology SIG workshop - The role of the laboratory in Clinical Pharmacology Practice
Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 3C
Facilitators: Dr Betty Exintaris, Assoc Prof Barbara Kemp-Harper and Assoc Prof Joseph Nicolazzo, Monash University Student facilitators: Saba Naghipour, Griffith University and Zahraa Abbas, Curtin University Introduction and overview Community engagement, Assoc Prof Joseph Nicolazzo, Monash University Industry experience, Steve Rees OBE, AstraZeneca, UK Career/professional development, Dr Kathleen Franklyn, Department of Training and Workforce Development Building strategic partnerships and working in clinical space, Steven Walker, Monash University Panel discussion Group discussion Group activity/challenge	Chair: Assoc Prof Cornelia Landersdorfer Lost in translation? Model-based translation of the time-course of drug effects, Prof Lena Friberg, Uppsala University, Sweden First-in-human dose selection and escalation – how modelling and simulation helps, Dr Tom Polasek, Certara Strategies and platforms to characterise drug metabolism in the lab, Assoc Prof Andrew Rowland 14:00 – 14:15 Drug Disposition and Response SIG AGM	Chairs: Prof David Joyce, Dr Rhonda Maguire, Assoc Prof Sar Salman The laboratory in Clinical Pharmacology Practice, Assoc Prof Sam Salman Oncology: Fluoropyrimidine dosing, Dr Rhonda Maguire, Pro Jennifer Martin Toxicology: Context dependence of drug/toxin discovery in human toxicology Prof David Joyce, Dr Sean O'Halloran Drug concentration measurement in infectious disease practice, Prof Debbie Marriott, Dr Sophie Stocker, Prof Jan-Willem Alffenaar Genotype discovery and drug
Wrap up	14:20 16:20	concentration measurement in psychiatric disorders, Prof
14:30 – 16:30	14:30 – 16:30	David Joyce, Dr Tom Polasek
Pharmaceutical Society of Australia (PSA) workshop	Drug Discovery SIG workshop - New frontiers in the translation of drug discovery into the patient	15:45 – 16:30 Clinical Pharmacology SIG AGM
Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	
Chair: Mayli Foong, PSA WA State Manager	14:30 – 14:50 Drug Discovery SIG Hybrid AGM	
14:30 – 15:30 Medicines by injection: Evolving role of pharmacists as the medicine experts, Keegan Wong, PSA WA Branch Committee 15:30 – 16:30 Aged care pharmacists: From advocacy to implementation, Ayomide Ogundipe, PSA WA Vice President	15:00 – 16:30 Mini symposium: Chairs: Dr Elizabeth Johnstone and Terrance Lam Validation of positive allosteric modulators for DOR to treat gastrointestinal motility disorders, Sadia Alvi, Monash University Solving the P2X1 receptor structure – a target	
Supported by Pharmaceutical Society of Australia	for male contraception, Felix Bennets, Monash University Screening assays for inhibitors against SARS-CoV-2 spike protein and cell entry, Dr Padraig Strappe, Curtin University	
	Molecular dynamics simulations reveals a novel cholesterol binding site for P2X7 receptors, Zheng (Jake) Chen, The University of Sydney The orexin receptors exhibit spatiotemporal signalling mechanisms in response to	
	endogenous ligands, Natasha Dale, Harry Perkins Institute of Medical Research Fragment screening against stabilised α1A- and α1B-adrenoceptors identifies novel sub-type selective antagonist, Dr Alaa Abdul-Ridah, The Florey Institute of Neuroscience and Mental Health	

16:30 – 17:00	Comfort break	
17:00 – 18:00	Conference opening	Supported by
	Room: Crown Ballroom 1	D 1
	Prof Kevin Pfleger, ASCEPT President Dr Petra Czarniak, APSA Conference Co-chair	ВЬ
	Opening keynote address	Bellberry
	Chair: Assoc Prof Daniel Wright, ASCEPT SAC Co-chair	Limited
	100. Keynote address Prof Sallie Pearson, Faculty of Medicine and Health, UNSW Sydney	research and ethics
18:00 – 19:30	Welcome reception	
	Room: Crown Ballroom 2	







Wednesday	30 November 2022			
07:30 – 18:00	Registration desk open Crown Ballroom Foyer			
08:00 - 08:50	British Pharmacological S Room: Crown Ballroom 1	Society keynote speaker		Supported by
		CCERT Procident		DAG! ODTGG!
	Chair: Prof Kevin Pfleger, AS			BMG LABTECH
	Steve Rees OBE, Vice President	ortunities in drug discovery dent Discovery Biology, AstraZ	eneca, UK	The Microplate Reader Company
09:00 – 10:30	CONCURRENT SESSION	1		
	Oral presentations 1: Pharmacy Practice	Oral presentations 2: Clinical Pharmacology	Oral presentations 3: Cardiovascular / Drug Discovery	Oral presentations 4: Toxicology / Drug Disposition and Response
	Room: Crown Ballroom 3A	Room: Crown Ballroom 1	Room: Crown Ballroom 3B	Room: Crown Ballroom 3C
	Chairs: Assoc Prof Lisa Kalisch Ellett and Lauren Fraser, University of South Australia	Chairs: Dr Tilenka Thynne, Flinders Medical Centre and Dr Frank Reimann, Taree Hospital and University of Newcastle	Chairs: Dr Simon Foster, QIMR Berghofer Medical Research Institute and Dr Alastair Keen, Monash University	Chairs: Assoc Prof Garth Maker, Murdoch University and Siobhonne Breen, Monash University
09:00 – 09:15	102. Early outcomes of video-assisted education for consumers prescribed oral anticoagulants Dr Leanne Chalmers, Curtin University	108. Drug Burden Index for deprescribing anticholinergic and sedative medications in older inpatients Dr Kenji Fujita, The University of Sydney; Kolling Institute, Royal North Shore Hospital	114. Adenosine receptor- mediated cardioprotection post-myocardial infarction in aged rats Dr Lauren May, Monash University	120. Substances detected in poisoning and non-poisoning related suicides in Australia Jessy Lim, The University of Sydney
09:15 – 09:30	103. Accuracy of best possible medication histories by pharmacy students: An observational study Martina Francis, The University of Sydney	109. Polypharmacy and the risk of QT prolongation in hospitalised patients on antipsychotics Tien Bui, University of South Australia	is a critical driver of angiotensin II-induced cardiac remodelling in mice Dr Narbada Saini, La Trobe University	121. Unintentional poisoning in older adults: Patterns in NSW Poisons Information Centre calls Qi Xuan Koh, UNSW Sydney
09:30 – 09:45	104. Estimating value of a pharmacist-led obstetric medicines information service through user experience Nabeelah Mukadam, King Edward Memorial Hospital	110. Carer Assessment of medicaTion management guidanCe for people with dementia at Hospital discharge Dr Mouna Sawan, The University of Sydney	116. Prevention of heart failure by adeno- associated virus directed expression of neuregulin1beta1 Dr Melissa Reichelt, The University of Queensland	122. The impact of medicinal cannabis legalisation and rescheduling on poisonings in Australia Sara Allaf, The University of Sydney
09:45 – 10:00	105. Community pharmacy training for people living with severe and persistent mental illness Ricki Ng, The University of Sydney	111. Using electronic prescription and laboratory data to assess prescribing practice Loma Pairman, University of Otago	117. The search for a ligand for the pro- atherosclerotic orphan GPCR, GPR146 Brendan Wilkins, UNSW Sydney	123. Exposure to ginseng increases oxidative stress and membrane fluidity of ram spermatozoa Tayler Catherine Kent, Murdoch University
10:00 – 10:15	106. The effect of COVID-19 on pharmacists' role as immunisers Maria Cooper, University of South Australia	112. Inappropriate prescribing and adverse health outcomes in hospitalised adults: A systematic review Dr Joshua Inglis, Flinders Medical Centre	118. Novel therapeutic agent to reverse atherosclerotic cardiovascular disease Assoc Prof Juliana Hamzah, Harry Perkins Institute of Medical Research	124. Extracellular vesicle derived biomarkers characterise physiological changes in cytochrome P450 activity Assoc Prof Andrew Rowland Flinders University
10:15 – 10:30	107. Perinatal depression screening recommendations and its implications in primary care Lily Pham, The University of Sydney	113. Patient-led gout management: Self-monitoring urate by people with gout improves clinical outcomes Toni Michael, The University of Sydney	119. Gene expression analyses of Tas1R taste receptors in cardiometabolic disease Mariah Stavrou, UNSW Sydney	125. Metabolic footprinting in a hollow-fibre infection model: Ceftolozane-tazobactam versus Pseudomonas aeruginosa Jessica Tait, Monash University


10:30 – 11:10	Morning tea with exhibitors Poster presentations: Pharmacoepidemiology, Drug	macy Practice, Drug Discover	y, Neuropharmacology, Jrogenital and Gastrointestinal	Supported by
	Room: Crown Ballroom 2			Curtin University
11:15 – 13:15	CONCURRENT SESSION	2		
	Symposium 1: Pathways exploiting NO mechanisms for targeting cardiovascular disease	Symposium 2: The multi-faceted approaches needed to address opioid related harms	Symposium 3: Pharmacology and toxicology of the gut, hepatobiliary and urogenital system: Challenges and therapeutic opportunities	Symposium 4: Partnerships, innovation and impact: Scaffolded learning approaches to research skill development
	Room: Crown Ballroom 1	Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 30
	Chairs: Prof Rebecca Ritchie, Monash University and Prof Chris Sobey, LaTrobe University	Chairs: Assoc Prof Bridin Murnion, St Vincent's Hospital and Dr Jessamine Soderstrom, The University of Western Australia	Chairs: Dr Scott Smid and Dr Ian Musgrave, The University of Adelaide	Chairs: Assoc Prof Kirstie Galbraith and Steven Walke Monash University
11:15 – 11:45	inflammatory resolution to improve endothelial function and vascular health: Targeting the non- canonical pathway for NO Prof Amrita Ahluwalia, Queen Mary University of London	130. Toxicovigilance to identify opioid harms and guide prevention Dr Rose Cairns, The University of Sydney	134. Hunting aldehyde-trapping drugs: Mechanistic considerations and their clinical potential in ALD Assoc Prof Philip Burcham, The University of Western Australia	138. An inquiring mind: Embedding a research culture in an undergraduate program Steven Walker, Monash University
11:45 – 12:15	127. Can we identify and correct aberrant NO signalling in clinical circumstances? Prof John Horowitz, The University of Adelaide	131. Improving opioid use for surgical patients Dr Jonathan Penm, The University of Sydney	135. Purinergic P2X7 receptor antagonism inhibits acrolein induced bladder damage: A potential antidote for cyclophosphamide toxicity Assoc Prof Liu Lu, UNSW Sydney	139. Implementation of an innovative flipped- model and longitudinal experience to enhance research training Asst Prof Kathryn Morbitzer, Center for Innovative Pharmacy Education and Research (CIPhER), USA
12:15 – 12:45	128. Exploiting NO mechanisms to protect the heart in diabetes and heart failure – the path favouring HNO Anida Velagic, Monash University	132. Implementation of take-home-naloxone by community pharmacists Dr Joanna Moullin, Curtin University	136. The role of the microbiome and probiotics in Parkinson's disease Jade Kenna, The University of Notre Dame; The University of Western Australia	140. Impact of Australia's first Pharmacy Student Research Journal using near-peer student review Verity Boustead, Joanne Wickens, Forrest Tang, National Australian Pharmacy Students' Association (NAPSA)
12:45 – 13:15	129. NO mechanisms to protect the vasculature in stroke Dr Daniel Beard, University of Newcastle	133. The development of evidence-based opioid deprescribing guidelines Aili Langford, The University of Sydney	137. Getting to the guts of polyherbacy: The role of herbal-interactions and cytotoxicity Dr Susan Britza, The University of Adelaide	141. Leveraging partnerships to drive innovation in research skills teaching and learning Dr Bianca Levkovich, Sandwell and West Birmingham NHS Trust, UK
13:15 – 14:10		rmacy Practice, Drug Discove g Disposition and Response,		Supported by UNSW
 13:25 – 14:10	Sciex Lunch workshop			Sponsored by
10.20 - 14.10	Room: Crown Ballroom 3A			opolisored by
	Can Time-of-Flight mass s	pectrometers benefit the clinovations are providing po		The Power of Precision

Pharmacy Practice	14:15 – 15:45	CONCURRENT SESSION 3				
Room: Crown Ballroom 3A Room: Crown Ballroom 3B Room: Crown Ballroom 3D Room: Crown Ballroom: Crown Ballroom 3D Room: Crown Ballroom: Crown Ballroom: Crown Ballroom: Crown Ballroom: Crown Ballroom: Crown Ballroom: Cr				Respiratory and	Oral presentations 8: Drug Discovery	
Chairs: Dr Vijay Supplah and Tien Bui, University of South Australia 4:15 – 14:30 142. A community phamacy ostooporosis screening service; an implementation science approach Jonathan Phuong, The University of Sydney 4:30 – 14:45 143. Clinicians' perspective of opioid analgesis the University of Sydney 4:30 – 14:45 144. A Clinicians' perspective of opioid analgesis the University of Sydney 4:30 – 15:00 144. Persistence with oral anticogulant therapy in atrial fibrillation: A cohort you farmarian and substitution of mobile respiratory function testing in Western Australian communities Dr Petra Czarniak, Curlin University of New England 145. A Delirium, length of stay and anticopressant withdrawal in an intensive care unit Army Kelty, University of New England 147. Patient-led gout management: People with gouts perspective on self-monitoring their urate Toni Michael, The University of Sydney of Sydney 1530 – 15:45 147. Patient-led gout management: People with gouts perspective on self-monitoring their urate Toni Michael, The University of Sydney of Sydney 1530 – 15:45 147. Patient-led gout management: People with gouts perspectives on self-monitoring their urate Toni Michael, The University of Sydney of Sydney 1530 – 15:45 147. Patient-led gout management: People with gouts perspectives on self-monitoring their urate Toni Michael, The University of Sydney of Sydney 1530 – 15:45 147. Patient-led gout management: People with gouts perspectives on self-monitoring their urate Toni Michael, The University of Sydney of Sydney 1530 – 15:45 147. Patient-led gout management: People with gouts perspectives on self-monitoring their urate Toni Michael, The University of Sydney 1530 – 15:45 1540 – 15:45 1551 – 15:45 1552 – 15:45 1554 – 15:45 1555 – 15:45 1555 – 15:45 1555 – 15:45 1555 – 15:45 1556 – 15:45 1556 – 15:45 1557 – 15:45 1557 – 15:45 1558 – 15:45 1558 – 15:45 1558 – 15:45 1558 – 15:45 1558 – 15:45 1559 – 15:45 1559 – 15:45 1559 – 15:45 1550 – 15:45 1550 – 15:45 1550 – 15:45			NAPE		Supported by TECAN•	
and Tien Bui, Úniversity of South Australia 14:15 – 14:30 142. A community pharmacy osteoporosis screening service; an implementation science approach Jonathan Phuong, The University of Sydney 4:30 – 14:45 143. Clinicians' perspective of opioid analgesic stewardship in acute pain clinical care standard Chelsea Dutkiewicz, The University of Sydney 4:45 – 15:00 144. Persistence with oral anticoagulant therapy in atrial fibrillation: A cohort study Adane Kefale, University of Tasmanis 150. Barriers and anticoagulant therapy in atrial fibrillation: A cohort study Adane Kefale, University of Daniel Malone, Monash University 5:00 – 15:15 145. An investigation of mobile respiratory function testing in Western Australian communities Dr Petra Cazamiak, Curin University 151. Delirium, length of stay and anticepessant withdrawal in an intensive care unit Army Kelty, University of New England 152. A science-themed escape room for teamwork withdrawal in an intensive care unit Army Kelty, University of New England 153. Development and waluation of a virtual privilege walk on self-prof Jane Bourke, Monash University of Sydney 153. Beronchodilation of priversity of Sydney 154. GPR84 antagonist, GLPG1205, reduced Stacky of Sydney 154. GPR84 antagonist, GLPG2705, reduced Stacky of Sydney 155. Patient-specific in human cells for disease features in experimental severe and privilege walk of Canberra 155. Patient-specific in human cells for disease features in experimental severe in processity of Melbourne in precision—cut tung silegation and inflammatory difference in human cells for disease features in experimental severe in processity in the University of Melbourne in processity		Room: Crown Ballroom 1	Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 3	
the pharmacy osteoporosis screening service; an implementation science approach Jonathan Phuong, The University of Sydney 4:30 – 14:45 4:30 – 14:45 143. Clinicians' perspective of opioid analgesic stewardship in acute pain clinical care standard Chelsea Durkiewicz, The University of Sydney 4:45 – 15:00 144. Persistence with oral anticoagulant therapy in atrial fibrillation: A cohort study Adane Kefale, University of Tasmania 5:00 – 15:15 145. Delirium, length of stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New England 5:15 – 15:30 146. Delirium, length of stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New England 5:30 – 15:45 147. Patient-led gout management: People with gour's perspectives on self-monitoring their urate Toin Michael, The University of Sydney pharmacy students ready? Entered asthma Dr Chantel abour keyperimental severe asthma Dr Chantel and Droversity of Sydney 149. Core concepts in pharmacy: Do they know? both kynow? Dr Alison Shield, University of Enhods to assess inhaled-toxicant susceptibility in fibrotic Rung disease Dr Simon Royce, Monash University or Simon Royce, Monash University or PR agonist Cmpd17b in precision-cut lural sides development of facilitators to implementing simulation into Pharmacy programs globally program		and Tien Bui, University of	Ricki Ng, The University of	Selemidis and Dr Simone De	Chairs: Assoc Prof Michell Halls, Monash University and Dr Nicholas Hunt, The University of Sydney	
of opioid analgesic stewardship in acute pain clinical care standard Chelsea Dulkiewicz, The University of Sydney 14:45 – 15:00 144. Persistence with oral anticoagulant therapy in atrial fibrillation: A cohort study Adane Kefale, University of Tasmania 150. Barriers and facilitators to implementing inflammatory effects of TepR agoin Exposition (Injurersity) 15:00 – 15:15 145. An investigation of mobile respiratory function testing in Western Australian communities Dr Petra Czarniak, Curtin University 15:15 – 15:30 146. Delirium, length of stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New England 152. A science-themed escape room for teamwork and critical thinking skills development Dr Iris Lim, Bond University 15:30 – 15:45 147. Patient-led gout management: People with gout's perspectives on self-monitoring their urate Tori Michael, The University of Sydney pharmacy: Do they know what they need to know? Dr Alisel of know? Dr Alastair Keen, Mona University of PPR agointator and anti-filammatory effects of FPR agoint Export The University of PPR agoint Export The University of Melbourne University of Melbourne 15:15 – 15:30 146. Delirium, length of stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New England 152. A science-themed escape room for teamwork and critical thinking skills development Dr Iris Lim, Bond University 153. Development and evaluation of a virtual privilege walk Dr Daniel Malone, Monash University of Sydney 154. Patient-led gout management: People with gout's perspectives on self-monitoring their urate Tori Michael, The University of Newseasti University of Sydney	14:15 – 14:30	pharmacy osteoporosis screening service; an implementation science approach Jonathan Phuong, The	entrepreneurship – Are pharmacy students ready? Dr Lynn Cheong, University	GLPG1205, reduces disease features in experimental severe asthma Dr Chantal Donovan, The University of Technology	Focus: Lentiviral-driven engineering of GPCRs in human cells for drug	
anticoagulant therapy in atrial fibrillation: A cohort study Adane Kefale, University of Tasmania 15:00 − 15:15 145. An investigation of mobile respiratory function testing in Western Australian communities Dr Petra Czarniak, Curtin University 15:15 − 15:30 146. Delirium, length of stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of England 15:30 − 15:45 147. Patient-led gout management: People with gout's perspectives on self-monitoring their urate Toni Michael, The University of Sydney anticoagulant therapy in atrial fibrillation: a facilitators to implementing simulation into Pharmacy of FPR agonist Cmpd17b in precision-cut lung slices of FPR agonist Cmpd17b in precision-cut lung slices Wifiliam Studley, Monash University of FPR agonist Cmpd17b in precision-cut lung slices Wifiliam Studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam tatory filips on the precision-cut lung slices wifiliam tatory filips on the precision-cut lung slices wifiliam tatory filips on the precision-cut lung slices wifiliam Studley, Monash University of Chantel Mastos, Mona University influence of GPCR Chantel Mastos, Mona University of Studiey, Monash University of Melbourne brait inhibitor precision-cut lung slices wifiliam studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam studley, Monash University of IPR agonist Cmpd17b in precision-cut lung slices wifiliam studley, Monash University of Melbourne or Studies in flammatory/fibrogenesis cytokines in alway epithelium Dr Qian Person of PCRC Charlet Mastos, Mona de IPR sequencion Dr Precision-cut lung slices wifiliam studley,	4:30 – 14:45	of opioid analgesic stewardship in acute pain clinical care standard Chelsea Dutkiewicz, The	pharmacy: Do they know what they need to know? Dr Alison Shield, University of	methods to assess inhaled-toxicant susceptibility in fibrotic lung disease Dr Simon Royce, Monash	targeted degradation of a GPCR Dr Alastair Keen, Monash	
of mobile respiratory function testing in Western Australian communities Dr Petra Czarniak, Curtin University 15:15 – 15:30 146. Delirium, length of stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New England 15:30 – 15:45 147. Patient-led gout management: People with gout's perspectives on self-monitoring their urate Toni Michael, The University of Sydney hepatitis-themed virtual escape room gamification in pharmacy education Dr Angelina Lim, Monash University of Melbourne 152. A science-themed escape room for teamwork and critical thinking skills development Dr Iris Lim, Bond University 158. Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University of Newcastle 159. Bronchodilation to FFA1/4 agonists is mairway epithelium Dr Qianyu Chen, The University of Melbourne 158. Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University of Newcastle 159. Bronchodilation to FFA1/4 agonists is mairway epithelium Dr Qianyu Chen, The University of Melbourne 158. Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University of Newcastle 159. Bronchodilation to FFA1/4 agonists is mairway epithelium Dr Qianyu Chen, The University of Melbourne 158. Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University of Newcastle 159. Bronchodilation to FFA1/4 agonists is mairway epithelium Dr Qianyu Chen, The University of Melbourne 158. Pirfenidone is more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University of Newcastle 159. Bronchodilation to FFA1/4 agonists is mairty apirotes in privilege walk University of Newcastle 159. Bronchodilation to Tellina Privilege walk University of	14:45 – 15:00	anticoagulant therapy in atrial fibrillation: A cohort study Adane Kefale, University of	facilitators to implementing simulation into Pharmacy programs globally Dr Daniel Malone, Monash	inflammatory effects of FPR agonist Cmpd17b in precision-cut lung slices William Studley, Monash	Chantel Mastos, Monash	
stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New England 15:30 – 15:45 147. Patient-led gout management: People with gout's perspectives on self-monitoring their urate Toni Michael, The University of Sydney escape room for teamwork and critical thinking skills development Dr Iris Lim, Bond University 15:30 – 15:45 Dr Iris Lim, Bond University 153. Development and evaluation of a virtual privilege walk Dr Daniel Malone, Monash University more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash University 159. Bronchodilation to FFA1/4 agonists is maintained in mouse allergic airways disease Assoc Prof Jane Bourke, Monash University of Tasmania	15:00 – 15:15	of mobile respiratory function testing in Western Australian communities Dr Petra Czamiak, Curtin	hepatitis-themed virtual escape room gamification in pharmacy education Dr Angelina Lim, Monash	inhibitor PF670462 inhibits inflammatory/fibrogenesis cytokines in airway epithelium Dr Qianyu Chen, The	microenvironmental features direct stem cells	
management: People with gout's perspectives on self-monitoring their urate Toni Michael, The University of Sydney evaluation of a virtual privilege walk Dr Daniel Malone, Monash University to FFA1/4 agonists is maintained in mouse allergic airways disease Assoc Prof Jane Bourke, Monash University of Tasmania	15:15 – 15:30	stay and antidepressant withdrawal in an intensive care unit Amy Kelty, University of New	escape room for teamwork and critical thinking skills development	more effective than glucocorticosteroids in limiting influenza-A-viral infection and inflammation Julia Chitty, Monash	approved drugs targeting TGF-β for chemoresistan high-grade serous ovaria	
15:45 – 16:10 Afternoon tea with exhibitors Supported by Respiratory and	15:30 – 15:45	management: People with gout's perspectives on self-monitoring their urate Toni Michael, The University	evaluation of a virtual privilege walk Dr Daniel Malone, Monash	to FFA1/4 agonists is maintained in mouse allergic airways disease Assoc Prof Jane Bourke,	165. Assessment of store operated calcium entry in cellular ageing models Vijayraghavan Seshadri, University of Tasmania	
	5:45 – 16:10	Afternoon tea with exhibitors	S	Supported by	Respiratory and Inflammation SIG AGM	

16:15 – 17:45	Certara New Investigator Award	Supported by	APSA AGM
	Room: Crown Ballroom 1	CERTARA	Room: Crown Ballroom 3A
	Chair: Assoc Prof Nicola Smith, ASC	EPT SAC Co-chair	
16:15 – 16:45	166. Structure-based discovery of new positive allosteric modulators of the A1 adenosine receptor Dr Anh Nguyen, Monash University		
16:45 – 17:15	167. Preclinical models to understal multiple concurrent medicines in ol up to? Dr John Mach, The University of Sydney.	d age: Where are we	
17:15 – 17:45	168. Novel targets for the treatment induced cognitive impairment in mi Dr Simone De Luca, RMIT University		
17:45 – 18:15	Student Forum AGM		
	Room: Crown Ballroom 1		
19:30 – 21:00	Student dinner		
	Venue: The Merrywell, Crown Perth	_	











The National Alliance for Pharmacy Education actively supports the ongoing advancement of the pharmacy profession. It views high quality, research-informed education as essential to supporting future positioning of the profession as a key contributor to the healthcare team.

Find out more at nape.edu.au




www.asceptasm.com

Thursday 1	December 2022			
07:30 – 17:00	Registration desk open Crown Ballroom Foyer			
08:00 - 08:50	CONCURRENT SESSION	4		
	ASCEPT Lecture		APSA Emerging Leaders Award	
	Room: Crown Ballroom 1		Room: Crown Ballroom 3A	
	Chair: Prof Kevin Pfleger, ASCEPT President		Chair: Dr Lisa Kalisch Ellett,	APSA Secretary
	Prof Rebecca Ritchie, Monash Sciences and Heart Failure Pr University		201. Co-designing deprescri implementation into hospita dementia Dr Nagham Ailabouni, The Uni	I for people living with
		erted by	202. Cell division as a target antimicrobial agents Dr Wern Chai, University of So	in the development of new
		Cai	203. Bridging the gap: Using competence to pharmacy st Dr Chiao Xin Lim, RMIT Unive	y vignettes to teach cultural udents
09:00 - 10:30	CONCURRENT SESSION	5		
	Oral presentations 9: Pharmacy Practice	Oral presentations 10: Clinical Pharmacology	Oral presentations 11: Cardiovascular	Oral presentations 12: Drug Discovery
	Room: Crown Ballroom 3A	Room: Crown Ballroom 1	Room: Crown Ballroom 3B	Room: Crown Ballroom 3C
	Chairs: Dr Leanne Chalmers and Dr Petra Czarniak, Curtin University	Chairs: Assoc Prof Jonathan Brett, St Vincent's Hospital; UNSW Sydney and Lorna Pairman, University of Otago	Chairs: Dr Michael De Silva, La Trobe University and Anida Velagic, Monash University	Chairs: Assoc Prof Daniel Scott, The University of Melbourne and Natasha Dale, University of Western Australia
09:00 – 09:15	204. Community pharmacists' acceptability of depression screening for older adults: A qualitative study Duha Gide, The University of Sydney	210. Carboplatin dose optimisation in the infant cancer patient Dr Shelby Barnett, Newcastle University	216. Cell therapy reduces vascular injury and cognitive impairment after hypertension and stroke Dr Michael De Silva, La Trobe University	222. Bias profile and efficacy-driven selectivity of xanomeline at the muscarinic receptor family Dr Celine Valant, Monash University
09:15 – 09:30	205. Attitudes of rheumatoid arthritis patients towards Disease Modifying Antirheumatic Drug deprescribing Lauren Fraser, University of South Australia	211. Feasibility of routine Therapeutic Drug Monitoring for 5-Fluorouracil Dr Peter Galettis, University of Newcastle	217. Antihypertensive effects of neurosteroid ganaxolone in two rodent models Cindy Gueguen, Baker Heart and Diabetes Institute	223. Investigating the pharmacological relationship between GPR161 and spexin-1 Kinjal Patel, UNSW Sydney
09:30 – 09:45	206. Sedative burden in hospitalised patients taking at least one antipsychotic medication Ruby Au, University of South Australia	212. Phase 1a/1b trial of a tight junction regulator (IMU-856) for coeliac disease Dr Tom Polasek, Certara	218. The citrus bioflavonoid hesperidin reverses metabolic and hepatic abnormalities in metabolic syndrome Dr Maria Jelinic, La Trobe University	224. Characterisation of Casein Kinase 1 Delta transcript variants in breast cancer tumourigenesis Jana Zielinski, The University of Melbourne
09:45 – 10:00	207. Patient reported experiences following implementation of the DBI Intervention Bundle in hospital Cristen George, The University of Sydney	213. Is Cannabidiol a clinically relevant anticancer drug? Edward Eden, University of Newcastle	219. The role of endothelial angiotensinll receptors in the release of nitric oxide Dr Lauren Phillips, University of Oxford	225. Gs priming of non- Gs protein activation and signalling at the glucagon- likepeptide-1 receptor John Azietaku, Monash University
10:00 – 10:15	208. Sleep health management in residential aged care facilities Elissar Mansour, The University of Sydney	214. Drug Burden Index Intervention Bundle for medication review: Patient and clinician experiences Dr Nashwa Masnoon, The University of Sydney; Royal North Shore Hospital	220. Effects of human amnion epithelial cells in experimental chronic stroke Dr Shenpeng Zhang, La Trobe University	226. Investigating the atypical DRY motif of the potential lipid-lowering orphan receptor GPR146 Hejie Zhang, UNSW Sydney
10:15 – 10:30	209. Impact of partnered pharmacist medication charting on potentially inappropriate medications use Tesfay Mehari Atey, University of Tasmania	215. An LC-MSMS assay of Cannabidivarin (CBDV) and metabolites Rebecca Gordon, University of Newcastle	221. Unravelling the intracellular signalling pathways in CGRP-induced vasorelaxation in rat coronary arteries Lucy Donovan, University of Oxford, UK	227. Fine-tuning glutamate receptor activity with allosteric inhibitors for neurodegenerative and psychiatric disorders Assoc Prof Karen Gregory, Monash University

10:30 – 11:10	Education, Pharmacy and Pl	s cology, Cardiovascular, Respira harmaceutical Sciences Educa maceutical Science, Innovatior	tion, Pharmacogenomics,	Supported by
11:15 – 13:15	CONCURRENT SESSION	6		PREMISORIE
	Symposium 5: Novel pharmacotherapies for chronic inflammatory diseases	Symposium 6: Translational pharmacology research to inform deprescribing for older people	Symposium 7: Drug Hypersensitivity reactions and the HLA system	Symposium 8: Advances in reproductive health research to address global challenges
				Supported by MONASH MEDICARS MANAFACTURINA CONTRE
	Room: Crown Ballroom 1	Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 3C
	Chairs: Prof Ross Vlahos, RMIT University and Dr Chantal Donovan, University of Technology Sydney	Chairs: Prof Sarah Hilmer, Kolling Institute, Royal North Shore Hospital; The University of Sydney and Assoc Prof Danijela Gnjidic, The University of Sydney	Chairs: Dr Duaa Gaafar, Royal Children's Hospital Melbourne and Dr Rhonda Maguire, PathWest Laboratory Medicine	Chairs: Dr Sab Ventura and Prof Michelle McIntosh, Monash University
11:15 – 11:45	228. Phosphodiesterase (PDE) Inhibitors as novel drugs for the treatment of respiratory diseases Prof Clive Page, King's College London, UK	232. Preclinical models to understand the risk of polypharmacy in old age Dr John Mach, The University of Sydney	236. Delayed drug hypersensitivity reactions: Clinical presentations, immune mechanisms, and common culprits Assoc Prof Sam Salman, University of Western Australia	240. Analysis of maternal medicines in drug development pipeline: Target product profile matching Dr Annie McDougall, Burnet Institute
11:45 – 12:15	229. Influenza A virus infection in pregnancy: Impacts beyond the lung Prof Stavros Selemidis, RMIT University	233. Pharmaco- epidemiologic research methods and findings to inform deprescribing practice Assoc Prof Andrew Zullo, Brown University, USA	237. Mechanisms of drug hypersensitivity and HLA Dr Andrew Gibson, Murdoch University	241. Inhaled oxytocin development for prevention of postpartum haemorrhage in low- resource settings Prof Michelle McIntosh, Monash University
12:15 – 12:45	230. Challenging the inhibitory/excitatory paradigm: Increased GABAergic inhibition can lead to epilepsy Prof Mary Chebib, The University of Sydney	234. Deprescribing trials: Challenges and pitfalls Prof Petra Thuermann, Witten/Herdecke University, Germany	238. Current and new technological advances to study HLA and drug interactions Dr Belinda Kaskow, University of Westem Australia	242. Spermatogenic targets for male contraception Dr Brendan Houston, The University of Melbourne
12:45 – 13:15	231. Innovative approaches to resolve inflammation in the heart and vasculature Dr Chengxue Helena Qin, Monash University	235. Co-design with consumers and clinicians to develop research priorities and deprescribing interventions Dr Emily Reeve, Monash University	239. HLA Pharmacogenomics in our region, stronger guidance for pre-emptive HLA testing needed Prof Andrew Somogyi, University of Adelaide	243. Cryo-EM structure of the human P2X1- purinoceptor for use in male contraception Dr Jesse Mobbs, Monash University
13:15 – 14:10	Lunch with exhibitors Poster presentations: Toxicology, Cardiovascular, Respiratory and Inflammation, Education, Pharmacy and		13:15 Gastro-Urogenital SIG	AGM
			Room: Crown Ballroom 3C	
	Pharmaceutical Sciences Ed	ducation, Pharmacogenomics,		
	Clinical Pharmacology, Phari Innovation and Industry	maceutical Science,	Room: Crown Ballroom 3A	
	Suppo	orted by	13:45 Neuropharmacology S	SIG AGM
	CERT	rara ^O	Room: Crown Ballroom 3B	
	Room: Crown Ballroom 2			

14:15 – 15:45	CONCURRENT SESSION	7		
	Oral presentations 13: Education	Oral presentations 14: Pharmacoepidemiology	Oral presentations 15: Neuropharmacology / Urogenital and Gastrointestinal	Oral presentations 16: Innovation and Industry Pharmaceutical Science
	Room: Crown Ballroom 1	Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 30
	Chairs: Dr Nilushi Karunaratne, Monash University and Dr Anna- Marie Babey, University of New England	Chairs: Dr Mouna Sawan and Dr Edwin Tan, The University of Sydney	Chairs: Prof Arthur Christopoulos, Monash University and Dr Iris Lim, Bond University	Chairs: Assoc Prof Stephanie Reuter Lange and Dr Tahlia Meola, University of South Austral
14:15 – 14:30	244. Potential factors that can affect the performance of undergraduate pharmacy research students Assoc Prof Nial Wheate, The University of Sydney	250. Evaluating collective impact theory as a catalyst for implementing population-level evidence-based deprescribing Dr Justin Turner, Monash University	256. Targeting inflammasome-dependent neuroinflammation in vascular dementia Prof Thiruma (Garrie) Arumugam, La Trobe University	262. Oral Nanotherapeutic formulations of GLP-1 agonist Liraglutide Dr Nicholas Hunt, The University of Sydney
14:30 – 14:45	245. Work-readiness of final year pharmacy students in undergraduate and graduate-entry programs Dr Rebecca Roubin, The University of Sydney	251. Deprescribing heart failure medications in older people: A systematic review and meta-analysis Mai Duong, The University of Sydney; Kolling Institute, Royal North Shore Hospital	257. Changes to the blood- brain barrier proteome in a mouse model of glioblastoma Dr Liam Koehn, Monash University	263. Multiplexed physiological perfusion systems for optimising the predictive value of drug screening Tianhong Cheng, The University of Melbourne
14:45 — 15:00	246. Improving the effectiveness of workplace-based assessment for intern pharmacists Dr Hayley Croft, University of Newcastle	252. Willingness of people living with cognitive impairment and their caregivers to deprescribe Dr Emily Reeve, Monash University	258. Rigorous pharmacological characterisation of metabotropic glutamate receptor 1 Dr Shane Hellyer, Monash University	264. Bacteriophage nanobots Dr Hien Duong, The University of Sydney
15:00 – 15:15	247. Professional hierarchies and status: Considerations for educational design of inter-professional student experiences Assoc Prof Kellie Charles, The University of Sydney	253. The association between medication discharge counselling and readmission to hospital Dr Edwin Tan, The University of Sydney	259. Desensitising properties of gain-of-function GABRB3 variants influence the severity of DEE Susan Lin, The University of Sydney	265. Systematic review of intravenous drug compatibility in neonatal intensive care setting Thisuri De Silva, Curtin University
15:15 – 15:30	248. Can brief whiteboard videos improve healthcare providers' knowledge and self-efficacy to deprescribe? Dr Justin Turner, Monash University	254. Prevalence of frailty in dementia and its association with medication use Linda Koria, The University of Sydney	260. Adenosine receptor modulators for the treatment of chronic pain Assoc Prof Wendy Imlach, Monash University	266. Effect on dissolution time after cutting a slow-release tablet formulation – Panadol-Osteo® Dr Kwang Choon Yee, University of Canberra
15:30 – 15:45	249. Cultivating interprofessional education for nursing and pharmacy students: A pilot study Dr Chiao Xin Lim, RMIT University	255. Effectiveness of bisphosphonates versus denosumab following hip fracture in people with dementia Dr Stephen Wood, Monash University	261. Bacteria and neuron interactions in the bladder Dr Luke Grundy, Flinders University	267. Development of a novel pH-buffered alginate gel for resistant wound infections Fatima Abid, University of South Australia


16:15 – 17:15	CONCURRENT SESSION 8				
16:15 – 16:45	ASCEPT Early Achievement Award for Women	APSA lecture			
	Room: Crown Ballroom 3A	Room: Crown Ballroom 1			
	Chair: Assoc Prof Nicola Smith, ASCEPT SAC Co-chair	Chair: Assoc Prof Joseph Nicolazzo, APSA President			
	268. Health and medication-related goals of care in Home Medicine Reviews Dr Lisa Kouladjian O'Donnell, The University of Sydney	A competent fit for purpose workforce: The journey from novice to expert Assoc Prof Kirstie Galbraith, Director, Experiential			
16:45 – 17:15	Equity, Diversity and Inclusion - The next steps for ASCEPT	Development and Graduate Education (EDGE), Monash University			
	Assoc Prof Tina Hinton, The University of Sydney				
17:15 – 18:15	ASCEPT AGM				
	Room: Crown Ballroom 3A				
19:00 – 23:30	Conference dinner	Supported by			
	Venue: Function Centre, Fraser's Kings Park, 60 Fraser Ave, Kings Park	Biodesign Australia			





Triday 2 Dec	cember 2022				
08:30 – 13:00	Registration desk open Crown Ballroom Foyer				
08:30 – 10:00	CONCURRENT SESSION 9				
	ASCEPT Garth McQueen s	tudent oral prize			
	Room: Crown Ballroom 1	<u> </u>			
	Chair: Assoc Prof Daniel Wri	ght, ASCEPT SAC Co-chair	-		
08:30 – 08:45	300. Exploring cardiac GPCI treatment Joel Coffie, Monash University				
08:45 – 09:00	301. Preventing urate-loweri flares: A systematic review a Dorsa Maher, University of Sou	and network meta-analysis			
09:00 – 09:15	302. The influence of soluble		Pharmaceutical Society of	Australia (PSA) lecture	
	tumour cell cytotoxicity of cl Xiaodan Zhang, The University		Room: Crown Ballroom 3A		
09:15 – 09:30	303. Adding a dimension to underlying IPF Avanka Gunatilaka, The Unive		Chair: Dr Petra Czarniak, Af 306. Never waste a good cris		
09:30 – 09:45	304. Effects of acute and chi oxide and simulated diabete Saba Naghipour, Griffith Unive	ronic trimethylamine-N- s in cardiac myoblasts	pharmacy practice Dr Fei Sim, National President, Pharmaceutical Society of Australia Supported by		
09:45 – 10:00	305. Sex differences in risk of cardiovascular events with Stablipree Sharma, Monash Un	SGLT2i versus GLP-1RAs	Pharr Socie	naceutical ty of Australia	
10:00 – 10:35	Morning tea with exhibitors Student poster finalist pres				
	Room: Crown Ballroom 2				
10:40 – 12:40	CONCURRENT SESSION	10			
	Symposium 9: Microphysiological Systems: Current innovations and projected impact on drug discovery and development	Symposium 10: Model informed precision dosing to battle AMR "from bedside to bench and back"	Symposium 11: Drug repurposing in the time of COVID-19	Symposium 12: The core concepts of pharmacology - so much content, so little time	
	Room: Crown Ballroom 1	Room: Crown Ballroom 3A	Room: Crown Ballroom 3B	Room: Crown Ballroom 30	
	Chairs: Prof Alastair Stewart, The University of Melbourne and Assoc Prof Yi-Chin Toh, Queensland University of Technology	Chairs: Prof Jan-Willem Alffenaar and Dr Sophie Stocker, The University of Sydney	Chairs: Tayler Kent, Murdoch University and Dr Susan Britza, University of Adelaide	Chairs: Assoc Prof Tina Hinton, The University of Sydney and Dr Suong Ngo University of Adelaide	
10:40 – 11:10	307. Human cardiac organoids as microphysiological systems to study peptide receptor function Dr Simon Foster, QIMR Berghofer Medical Research Institute	311. Why are changes needed in drug dosing for infectious diseases? Assoc Prof Sam Salman, The University of Western Australia	315. Lost in Translation? Insights from drug repurposing for COVID Prof Craig Rayner, Monash University	319. A perspective on "knowledge" curricula - what do pharmacists need to know Prof Timothy Chen, The University of Sydney	
11:10 – 11:40	308. Nociceptive detection using a cell-based microfluidic platform Dr Tommy Tong, Monash University	312. How can preclinical studies be used for establishing drug concentration targets? Dr Fekade Sime, The University of Queensland	316. The valley of death - why Australia failed to develop clinically effective drugs in COVID-19 Prof Jennifer Martin, University of Newcastle	320. Student learning: Context matters Emeritus Prof Patangi (Char Rangachari, McMaster University, Canada	

11:40 – 12:10	309. Multiplexed superfusion system for cell culture: From prototype to product Dr Bryan Gao, The University of Melbourne	313. Developing pharmacokinetic models for clinical care; how can we make them useful? Assoc Prof Cornelia Landersdorfer, Monash University	317. Australian program for drug repurposing for treatment resistant ovarian cancer Prof Nikola Bowden, University of Newcastle; Hunter Medical Research Institute	321. Core concepts of Pharmacology Education: An international collaboration for students and educators Prof Clare Guilding, University of Newcastle, UK
12:10 – 12:40	310. Scalable models for disease modelling and drug testing Prof Yi-Chin Toh, Queensland University of Technology	314. Ahead of the curve with Vancomycin dosing in children Mr Tony Lai, Westmead Children's Hospital	318. Repurposing medicines in Australia Nick Henderson, Therapeutic Goods Administration	322. Core concepts, concept inventories and pedagogical content knowledge Prof Paul White, Monash University
12:45 – 13:30	APSA Medalist			
	Room: Crown Ballroom 1			
	Chair: Assoc Prof Joseph Nicolazzo, APSA President			
	Assoc Prof Stephanie Reuter Lange, University of South Australia			
13:30 – 14:00	Awards and conference close			
	Prof Kevin Pfleger, ASCEPT President Assoc Prof Joseph Nicolazzo, APSA President			
14:00	Lunch			
	Room: Crown Ballroom 2			



International Congress of Therapeutic Drug Monitoring & Clinical Toxicology



Singapore 2025

Register your interest: www.iatdmct2025.org

20th World Congress of Basic and Clinical Pharmacology #WCP2026 | wcp2026.org









PRINCIPAL SPONSOR

Bb Bellberry Limited supporting research and ethics

MAJOR SPONSORS





The Microplate Reader Company







CONFERENCE DINNER SPONSOR

LUNCH WORKSHOP SPONSOR





SUPPORTERS













CONTRIBUTOR







LANYARD SPONSOR



EXHIBITORS













SUPPORTED BY







Conference Secretariat



T. +61738482100

E. apsa-ascept@expertevents.com.au PO Box 351, Hamilton Central QLD 4007 Australia Suite 11, 137 - 143 Racecourse Road, Ascot QLD 4007